In our previous studies, we observed that the TBK1 inhibitor BX795 and Tbk1 siRNA prevent via p16INK4a inhibition RGC senescence in a mouse model of glaucoma, thus, providing a promising target for a molecular glaucoma therapy (Li et al., 2017). The gene discussed is CDKN2A; the disease is glaucoma.